Physician profile
Mark Borowsky
NPI 1871570044
$17,333.39
in general payments reported to CMS, 2019-2025
18 companies · $201 in 2025
The $201 reported for 2025 was less than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $423 · 2020: $2,375 · 2021: $11K · 2022: $2,945 · 2023: $186 · 2024: $243 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $630.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $8,729.51 | 2021 | |
| Glaxosmithkline, LLC. | $5,381.39 | 2020-2025 | Zejula, Jemperli |
| Astrazeneca Pharmaceuticals Lp | $2,144.97 | 2021-2025 | |
| Tesaro, INC. | $400.00 | 2019 | |
| Merck Sharp & Dohme LLC | $155.78 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Eisai INC. | $125.91 | 2021-2025 | |
| Abbvie INC. | $62.94 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $62.05 | 2021-2024 | Myrisk |
| Medtronic, INC. | $50.49 | 2022 | |
| Ethicon US, LLC | $40.51 | 2023-2024 | Stratafix, Echelon Flex, Enseal |
| Genmab U.S., INC. | $32.42 | 2022-2023 | Tivdak |
| Hologic Sales and Service, LLC | $32.16 | 2021-2023 | Coolseal Generator |
| Clovis Oncology, INC. | $28.35 | 2021-2022 | |
| Immunogen, INC. | $27.55 | 2023-2024 | Elahere, Elahere |
| Becton, Dickinson and Company | $22.89 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $21.76 | 2023 | |
| Pfizer INC. | $14.71 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Borowsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.